<DOC>
	<DOCNO>NCT01657981</DOCNO>
	<brief_summary>The study aim observe YM150 absorb , distribute excrete dose radio label drinking solution .</brief_summary>
	<brief_title>A Study Find Out How YM150 Absorbed Into Eliminated From Body Healthy Male Subjects</brief_title>
	<detailed_description>Healthy male subject admit Day 0 . Subjects receive single oral dose 14C-labeled YM150 morning Day 1 remain unit 7 day ( 6 night ) . Blood , plasma , urine feces sample collect 120 hr dose analysis 14C-labeled radioactivity , YM150 , YM-222714 metabolite . Expired air collect well assessment 14C-radioactivity .</detailed_description>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Body weight 60 100 kg Body Mass Index 18 30 kg/m2 Known suspected hypersensitivity YM150 constituent formulation use History and/or sign symptom indicate current abnormal hemostasis blood dyscrasia , include limited neutropenia , thrombocytopenia , thrombocytopathy , thromboasthenia , hemophilia , Von Willebrand 's disease , vascular purpura , bleed gum frequent nose bleed Family history congenital vascular malformation ( e.g . Marfan 's Syndrome ) and/or bleed disorder ( e.g . hemophilia , Von Willebrand 's disease , Christmas disease ) History peptic ulcer organic lesion susceptible bleed Prothrombin time ( PT ) Activated partial thromboplastin time ( aPTT ) screen visit outside normal range Any surgical intervention ( include tooth extraction ) trauma within last 3 month precede start study Any clinically significant history asthma , eczema , clinically significant allergic condition previous severe hypersensitivity drug Any clinically significant upper gastrointestinal symptom likely interfere absorption drug History presence cardiovascular disease disorder History clinically significant ECG abnormality Any clinically relevant history disease disorder gastrointestinal , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic Any clinically significant abnormality follow Investigator 's review prestudy physical examination , ECG , clinical laboratory test Abnormal heart rate blood pressure measurement screen visit follow : heart rate &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &lt; 95 &gt; 160 mmHg ; mean diastolic blood pressure &lt; 40 &gt; 95 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ) Regular use prescribe OTC drug ( include vitamin herbal remedy ) 4 week prior admission clinical unit OR use drug 2 week prior admission clinical unit History drug abuse time , OR use drug abuse within 3 month prior admission clinical unit Participation clinical study within 3 month , participation 3 clinical study within 12 month , prior expect date enrolment study History drink 21 unit alcohol per week ( 1 unit = 270 ml beer 40 ml spirit 125 ml wine ) within 3 month prior admission clinical unit History smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission clinical unit Subject , antiHAV ( IgM ) , antiHCV , HBsAg HIV1 2 positive Donation blood ( &gt; 400 ml ) blood product within 3 month prior admission clinical unit plasmapheresis within 4 week prior admission clinical unit Exposure radiation diagnostic reason ( except dental Xrays plain Xrays thorax bony skeleton ( exclude spinal column ) ) , work participation clinical study previous year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>14C-labeled</keyword>
</DOC>